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   Jennifer S. Smith is an Associate Professor of Department of 
Epidemiology, Gillings School of Global Public Health, University 
of North Carolina. Dr. Smith is also affiliated with the UNC 
Lineberger Comprehensive Cancer Center (Cancer Epidemiology), 
UNC Center for AIDS Research, and the UNC Center for Women’s 
Health Research. Dr. Smith has conducted research on HPV infection 
and associated cervical neoplasia since 1995. Her current research 
focuses on epidemiological studies of human papillomavirus 
(HPV) and cervical cancer worldwide (primarily in Kenya, South 
Africa, China, and North Carolina), with a focus on prevention via 
screening, HPV self-screening and prophylactic vaccines. 
1. As we know, you are the principal investigator of the 
Cervical Cancer-Free Initiative. How long have you been 
involved in the study of preventing cervical cancer?
   I started working on cervical cancer prevention when I was a PhD 
student at Johns Hopkins in 1994, which is unbelievably over 20 
years ago. The field of cervical cancer has dramatically changed 
since I began studying HPV and cervical cancer. Prophylactic HPV 
vaccines are currently available and have the potential to prevent 
70% of invasive cervical cancer worldwide. We also have HPV 
testing which is available for women 30 years or older that can 
dramatically improve the sensitivity of cervical cancer screening. 
These two innovations will be forefront in our fight against this 
preventable cancer. 
 
2. Which country or what kind of regions have you done 
this investigation before? And what kinds of female 
groups have been involved in this investigation?
   I have been fortunate to be involved in several global projects 
in many countries worldwide. The focus of my research is on 
epidemiological studies of HPV and cervical cancer worldwide 
(primarily in China, Kenya, South Africa, and North Carolina), 
with a focus on prevention via screening, HPV self-screening and 
prophylactic vaccines. 
 
3. You are an Associate Editor of Sexually Transmitted 
Infections and on the editorial board of Sexually 
Transmitted Diseases. What are your achievements in 
sexually transmitted infections? Please make a brief 
introduction.
   I am particularly interested in the intersection of sexually 
transmitted infections and cancer risk. For example, my 
collaborative work with the international agency for cancer research 
in Lyon, France identified that chlamydia trachomatis infections 
seemed to be consistently associated with an increased risk of 
invasive cervical cancer. I have also published over 210 articles in 
international peer-reviewed journals, of which over 170 are related 
to HPV infection and HPV-associated diseases, including cervical, 
anal, vaginal, vulvar and penile cancer.
 
4. The project aimed at preventing cervical cancer 
through vaccination against HPV is also one of your 
principal researches. What is the specific efficacy of HPV 
vaccines so far? How about the progress in HPV vaccines 
research?
   There are currently two prophylactic HPV vaccines available to 
prevent cervical cancer. Both of theses vaccines have been shown 
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to be incredibly protective against the development of high-grade 
cervical pre-cancer with nearly one hundred percent efficacy against 
high-grade cancerous lesions associated HPV vaccine types. One is 
the quadrivalent vaccine (including HPV types 6, 11, 16 and 18) and 
other other is a bivalent vaccine (including HPV types 16 and 18).
 
5. Do HPV vaccines have side effects? Could you tell us its 
potential side effects?
   The vaccine has been very well studied and is an extremely safe 
vaccine. It is important to note that these virus like particle vaccines 
contain no infectious HPV. Data from the United State’s Center for 
Disease Control shows that with more than 23 million doses of HPV 
vaccine administered, there have been 12 424 reports of adverse 
events after vaccination. However, most (94%) adverse events were 
not serious. The most common events include local reactions at the 
site of immunization (pain and redness) and sometimes dizziness, 
nausea, headache, and fainting can occur. 
 
6 .  In  2013 ,  you  publ i shed  an  ar t i c l e  ent i t l ed 
“Recommendations for a national agenda to substantially 
reduce cervical cancer.” In May 2011, Cervical Cancer-
Free America, a national initiative, convened a cervical 
cancer summit in Washington, DC. Over 120 experts 
from the public and private sector met to develop a 
national agenda for reducing cervical cancer morbidity 
and mortality in the USA. And the summit also offered 12 
concrete recommendations to guide future national and 
local efforts toward this goal. Could you talk about the 12 
concrete recommendations from this summit briefly?
    The 12 recommendations from the summit are as follows:
   Recommendation 1: Ensure that underserved women know what 
preventive services are available and where to access them.
   Recommendation 2: Advocate for coverage of evidence-based 
screening, diagnostic, and treatment services for all underserved 
women.
   Recommendation 3: Improve information sharing among 
healthcare delivery systems.
   Recommendation 4: Advocate for increased funding to National 
Breast and Cervical Cancer Early Detection Program (NBCCEDP).
   Recommendation 5: Reach women when they come into contact 
with the healthcare system.
   Recommendation 6: Encourage and reinforce the need for 
providers to follow current screening guidelines.
   Recommendation 7: Establish state registries to improve screening 
and follow-up care.
   Recommendation 8: Educate providers, patients, and the public.
   Recommendation 9: Expand school-located HPV vaccination 
programs.
   Recommendation 10: Expand HPV vaccination within pharmacies 
and alternate delivery sites.
   Recommendation 11: Advocate for increased use of HPV 
vaccination registries with recall systems.
   Recommendation 12: Facilitate Medicaid and other programs to 
reimburse HPV vaccination, including allowing alternative delivery 
sites to become in-network providers.
 
7. Concerning these 12 concrete recommendations, which 
institutions or hospitals have implemented?
   There is a number of organizations, and individuals who are 
working towards global cervical cancer. I think the notion of freedom 
against cervical cancer belongs to everyone, so it is about individuals, 
communities, organizations, and survivors coming together to make 
a difference on a local level to reduce this preventable cancer. 
 
8. Currently, you visit HK, China and Singapore for 
academic exchanges. Do you have any research topics 
about cervical cancer?
   I think that there is a lot of opportunity to work together to prevent 
cervical cancer. With the dramatic economic transition in Asia, we 
have a tremendous potential to reduce cervical cancer and other 
HPV associated cancer in these Asian countries. Given that we 
have vaccines that can successfully prevent infections and are safe, 
I think that one of the biggest research questions is ‘how can we 
successfully optimize vaccine coverage among young adolescents?’. 
Further, given that we have improved HPV testing methods to 
imporve cervical cancer screening, we need investigate to understand 
more, both from the provider and patient prospective. We also need 
to investigate how to ensure available access to these preventative 
tools to all women (screening) and young adolescents (vaccination). 
 
9. Could you talk about the prospect of preventing cervical 
cancer?
   I think that we now have an unprecedented opportunity to 
dramatically reduce cervical cancer. It is incredible that over 280 000 
women die from a preventable cancer. With the tools of vaccination, 
improved screening and associated treatments, we have the tools to 
potentially eliminate cervical cancer. Now is the time for action to 
reduce this highly preventable disease!
